
==== Front
Open Heart
Open Heart
openhrt
openhrt
Open Heart
2053-3624
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39214537
10.1136/openhrt-2024-002801
openhrt-2024-002801
Original Research
Valvular Heart Disease
1506
Hypercapnia during transcatheter aortic valve replacement under monitored anaesthesia care: a retrospective cohort study
http://orcid.org/0000-0003-3508-1528
Chen Tzonghuei 1herbchen@gmail.com

Asher Shyamal 1Shyamal_asher@brown.edu

Apruzzese Patricia 1tapruzzese@gmail.com

Owusu-Dapaah Harry 1howusudap@gmail.com

Gonzalez Gustavo 2gustavo_gonzalez@alumni.brown.edu

Maslow Andrew 1amaslow@rcn.com

1 Department of Anesthesiology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA
2 Department of Anesthesiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Dr; herbchen@gmail.com
None declared.

2024
30 8 2024
11 2 e00280124 6 2024
19 8 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Background

Acute intraoperative hypercapnia and respiratory acidosis, which can occur during monitored anaesthesia care (MAC), pose significant cardiopulmonary risks for patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). The goal of the present study is to assess the incidence, risk factors and impact of intraoperative hypercapnia during MAC for patients undergoing transfemoral TAVR.

Methods

Data was collected retrospectively from the electronic medical record of 201 consecutive patients with available intraoperative arterial blood gas (ABG) data who underwent percutaneous transfemoral TAVR with MAC using propofol and dexmedetomidine. ABGs (pH, arterial partial pressure of carbon dioxide (PaCO2) and arterial partial pressure of oxygen) were performed at the start of each case (baseline), immediately prior to valve deployment (ValveDepl), and on arrival to the postanaesthesia care unit. Data was analysed using Fisher’s exact test, unpaired Student’s t-test, Wilcoxon rank sum or univariate linear regression as appropriate based on PaCO2 and pH during ValveDepl (PaCO2-ValveDepl, pH-ValveDepl) and change in PaCO2 and pH from baseline to ValveDepl (PaCO2-%increase, pH-%decrease) to determine their association with preoperative demographic data, intraoperative anaesthetic and vasoactive medications and postoperative outcomes.

Results

PaCO2 increased by a mean of 28.4% and was higher than baseline in 91% of patients. Younger age, male sex, increased weight and increased propofol dose contributed to higher PaCO2-ValveDepl and greater PaCO2-%increase. Patients with PaCO2-ValveDepl>60 mm Hg, pH≤7.2 and greater pH-%decrease were more likely to receive vasoactive medications, but perioperative PaCO2 and pH were not associated with adverse postoperative outcomes.

Conclusions

Transient significant hypercapnia commonly occurs during transfemoral TAVR with deep sedation using propofol and dexmedetomidine. Although the incidence of postoperative outcomes does not appear to be affected by hypercapnia, the need for vasopressors and inotropes is increased. If deep sedation is required for TAVR, hypercapnia and the need for haemodynamic and ventilatory support should be anticipated.

Transcatheter Aortic Valve Replacement
Hypertension, Pulmonary
Aortic Valve Stenosis
==== Body
pmcWHAT IS ALREADY KNOWN ON THIS TOPIC

Acute intraoperative hypercapnia can occur during monitored anaesthesia care (MAC) and may pose significant cardiopulmonary risk in patients undergoing transcatheter aortic valve replacement (TAVR), especially because patients with aortic stenosis and heart failure often present with underlying respiratory dysfunction and baseline hypercapnia.

WHAT THIS STUDY ADDS

Hypercapnia commonly occurs in patients undergoing TAVR with MAC and is associated with an increase in vasoactive medication use.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

Physicians providing sedation to patients undergoing TAVR must be aware of the possibility of severe hypercapnia in this patient population and should be prepared to administer haemodynamic and ventilatory support.

Introduction

Transcatheter aortic valve replacement (TAVR) is a safe and effective treatment option for adults with severe symptomatic aortic stenosis (AS).1 2 With the majority of TAVR now being performed via the percutaneous transfemoral approach,35 anaesthetic choice has shifted from general anaesthesia (GA) to monitored anaesthesia care (MAC) and moderate sedation,68 with reported benefits including improved haemodynamic stability, shorter procedure times, reduced hospital length of stay (LOS) and intensive care unit (ICU) LOS, faster recovery, decreased respiratory complications, reduced costs and reduced in-hospital and 30-day mortality.6916

Sedation techniques during MAC vary, with anaesthetic depth ranging from minimal to deep sedation, the latter being similar to GA without controlled ventilation.34 8 9 11 1719 Because many anaesthetic medications decrease central respiratory drive and cause upper airway obstruction, deeper sedation may lead to hypercapnia and other adverse respiratory events such as atelectasis, respiratory depression and subsequent oxygen desaturation and hypoxemia when compared with minimal or moderate sedation or GA with a secured airway and controlled ventilation.112025 While acute mild hypercapnia in the perioperative period is generally reversible and well tolerated,2628 severe hypercapnia in the presence of acidosis can be associated with cardiopulmonary and neurocognitive dysfunction.2933

Patients with AS may present for TAVR with respiratory dysfunction, sleep disordered breathing and hypercapnia related to heart failure and pulmonary oedema.3436 They are also at risk for cardiovascular complications, especially those presenting with pulmonary hypertension,3743 and may be susceptible to the physiologic sequelae of hypercapnia, acidosis and hypoxemia.

The primary goal of the present study is to assess the incidence and risk factors of intraoperative hypercapnia in patients with AS undergoing transfemoral TAVR with MAC. Secondarily, the impact of hypercapnia on perioperative outcomes is analysed. We hypothesise that hypercapnia commonly occurs but is transient and does not impact postoperative outcomes.

Methods

Study population

This retrospective cohort study included patients undergoing non-emergent percutaneous transfemoral TAVR under MAC with the Edwards Sapiens valve (Edwards Lifesciences, Irvine, California, USA) between 1 April 2019 and 31 March 2022. Patients without intraoperative arterial blood gas (ABG) data available in the electronic medical record (EMR) were excluded. Out of 655 patients who underwent percutaneous transfemoral TAVR during the study period, ABG data were available for 201 patients.

Anaesthetic conduct

The standard anaesthetic technique for TAVR at our institution is MAC. GA is reserved for patients with anticipated intolerance to sedative medications or for those undergoing alternative access TAVR. Routine clinical practice includes preoperative intravenous catheter placement, standard American Society of Anesthesiologists non-invasive monitoring, an arterial line for invasive blood pressure monitoring and the Bispectral Index Monitoring System (BIS, Medtronic, Minneapolis, Minnesota, USA) for depth of sedation monitoring. In addition, ABG analyses are performed regularly using the GEM Premier 4000 (Werfen, Bedford, Massachusetts, USA).

In the operating room, all patients receive supplemental oxygen (8 L/min) via non-rebreather facemask. Anaesthetic medications routinely administered include a combination of dexmedetomidine and propofol infusions titrated to optimise patient comfort, minimise patient movement and preserve spontaneous ventilation. Additional medications, including midazolam, fentanyl and ketamine, are administered at the discretion of the attending anaesthesiologist.

Intraoperative hemodynamics are managed by the anaesthesiologist using intravenous vasoactive medications as needed. Vasopressors include norepinephrine, phenylephrine and/or vasopressin. Inotropes include epinephrine administered to patients with severe myocardial dysfunction.

Post procedure, patients are either brought to the postanaesthesia care unit (PACU) or the Coronary Care Unit if they actively require infusions of vasoactive medications, transvenous pacing and/or if they experienced procedural complications.

Data

Data was collected retrospectively from the EMR of patients included in the study. Preoperative demographic data included age, sex, weight and body mass index (BMI). Baseline pulmonary data included the presence of chronic obstructive pulmonary disease (COPD), home oxygen requirement, obstructive sleep apnoea (OSA) and history of smoking (never, former or current). Additional preoperative end organ function data included renal glomerular filtration rate (GFR, mL/min), left ventricular ejection fraction (LVEF, %) and right ventricular systolic pressure (RVSP, mm Hg).

Analysed ABG data included the pH, arterial partial pressure of carbon dioxide (PaCO2) and arterial partial pressure of oxygen (PaO2) at three time points: baseline, valve deployment (ValveDepl) and PACU. The baseline ABG was obtained prior to sedation while receiving supplemental oxygen. The next ABG was obtained intraoperatively after heparin administration and immediately prior to ValveDepl (pH, PaCO2 and PaO2-ValveDepl). The PACU ABG was performed in the immediate postoperative period on arrival to PACU before removing the non-rebreather facemask. The per cent increase in PaCO2 from baseline to sedation (PaCO2-%increase) and per cent decrease in pH from baseline to sedation (pH-%decrease) was calculated using the equations:

PaCO2%increase=(PaCO2ValveDepl−PaCO2baseline)×100÷PaCO2baseline 

pH%decrease=(pHbaseline−pHValveDepl)×100÷pHbaseline

Intraoperative BIS data was recorded from the EMR at the ValveDepl time point.

Operating room time was defined as the length of time between arrival to the operating room and departure from the operating room.

Doses of midazolam, fentanyl and ketamine were recorded from the EMR. The total doses of propofol and dexmedetomidine administered were also recorded and then divided by patient weight and operating room time to obtain an average administration rate over the duration of the case (µg/kg/min for propofol and µg/kg/hour for dexmedetomidine).

Vasoactive medications

Administration of vasopressors or inotropes during the case (any vs none) and just prior to ValveDepl (any vs none) was recorded. The total administered vasopressor and inotrope medication dose was measured in ‘vasopressor equivalents’ (µg) adapted from the equation described by Goradia et al44:

Total vasopressor equivalents(μg)=norepinephrine(μg)+epinephrine(μg)+phenylephrine(μg)÷10+vasopressin(units)×2.5

This was then divided by operating room time and patient weight to obtain average vasopressor equivalents (µg/kg/min) for the case duration.

Postoperative outcomes

Postoperative outcome variables included postprocedure hospital LOS, ICU LOS and 30-day mortality. Postoperative delirium, stroke and need for postoperative pacemaker insertion were also recorded.

Statistical analysis

The associations between PaCO2-ValveDepl and PaCO2-%increase and independent variables such as demographic data (age, sex, weight, BMI), end organ function (COPD, asthma, home O2 dependence, smoking status, LVEF, RVSP, GFR), administered anaesthetic and vasoactive medications, BIS and postoperative outcome variables were analysed. The normal range for PaCO2 is 35–45 mm Hg and a normal pH ranges between 7.35 and 7.45. Definitions of mild, moderate and severe hypercapnia vary and studies arbitrarily select PaCO2 cut-offs for analyses. Mild-to-moderate elevations of PaCO2 are described between 45 and 60 mm Hg, becoming severe with PaCO2>60 mm Hg and pH<7.25.262830 45 Hypercapnic acidosis with PaCO2>60 mm Hg and pH<7.20 is associated with worse outcomes.2930 4547

ABG data was therefore analysed based on PaCO2-ValveDepl (≤60 mm Hg and >60 mm Hg), pH-ValveDepl (≤7.2 and >7.2) and PaCO2-%increase (≤50% and >50%). Categorical variables were reported as counts and percentages and continuous variables as mean±SD. Categorical variables were analysed with Fisher’s exact test. Continuous variables were analysed using unpaired Student’s t-test or Wilcoxon rank sum (two group comparison) as appropriate after being assessed for normality. To assess the changes in PaCO2, PaO2 and pH over the course of the study (Baseline, ValveDepl, PACU), repeated measures generalised linear mixed models were used.

PaCO2-ValveDepl, PaCO2-%increase, pH-ValveDepl and pH-%decrease were also analysed as continuous variables using univariate regression models to examine their linear relationships with the above independent variables. This same analysis was repeated for RVSP groups of <40 mm Hg, 40–60 mm Hg and RVSP>60 mm Hg to analyse the effects of hypercapnia on outcomes in patients with pre-existing pulmonary hypertension.

In a series of separate analyses, to better elucidate the variables affecting vasopressor administration, univariate linear regression models were used to describe the linear relationship between infusion rates of propofol and dexmedetomidine and BIS and average vasopressor equivalents. Next, patients who were administered a vasopressor during the case were compared with those who did not using the methodology described above for two group comparisons. A similar analysis was conducted for administration of inotrope.

In addition, the linear relationships between the above independent variables and ICU LOS and postprocedure hospital LOS were analysed using univariate linear regression models, while the association between the above independent variables and need for ICU admission, postoperative delirium, stroke and need for postoperative pacemaker insertion were analysed using unpaired Student’s t-test or Wilcoxon rank sum and Fisher’s exact test.

A threshold of 0.05 was used for statistical significance in all analyses and p values were two sided. All statistical analyses were conducted with the use of SAS software V.9.4.

Results

201 patients were included in the data analysis (dataset).48 The mean age of the study population was approximately 79 years. Preoperative demographic data are found in table 1.

Table 1 Demographic data

Sex		
 Female % (n)	40.3% (81)	
 Male % (n)	59.7% (120)	
Age		
 Mean±SD (range)	78.7±8.8 (49-100)	
Body mass index		
 Mean±SD (range)	29.0±5.3 (18.7–48.0)	
Weight (kg)		
 Mean±SD (range)	81.8±17.8 (43.5–147.4)	
Chronic obstructive pulmonary disease	17.4% (35)	
Asthma	13.9% (28)	
Smoking status		
 Never % (n)	37.8% (76)	
 Former % (n)	57.7% (116)	
 Current % (n)	4.5% (9)	
Obstructive sleep apnoea % (n)	21.9% (44)	
Home oxygen % (n)	2.5% (5)	
Glomerular filtration rate (mL/min)		
 Mean±SD (range)	54.7±10.0 (6-60)	
Left ventricular ejection fraction (%)		
 Mean±SD (range)	58.5±13.8 (10-80)	
Right ventricular systolic pressure (mm Hg)		
 Mean±SD (range)	37.6±12.8 (18-90)	

Medications

All but one patient received both propofol and dexmedetomidine infusions. The average propofol dose (µg/kg/min) was found to be inversely correlated with age (p=0.0037). 92 patients (45.8%) received 1–4 mg of midazolam, 59 (29.4%) received 25–100 µg of fentanyl and 7 (3.5%) received 25–100 mg ketamine injections. 91% (182/201) of all cases received a vasopressor at some point during the case.

The mean BIS at the time of ValveDepl was 48. In a univariate linear regression analysis, lower BIS was associated with higher total dose (p=0.009) and average infusion rate (p=0.0001) of propofol, as well as total midazolam dose (p=0.0047).

There were no significant linear associations between BIS or amount of dexmedetomidine or propofol administered and total or average vasopressor equivalents. Preoperative RVSP was not associated with the intraoperative administration of a vasoactive medication, while a reduced LVEF (40.0%±15.8% vs 59.2%±13.3%) was associated with more frequent inotrope use (p=0.002). Other predictors of inotrope use included longer procedure time (53.4 vs 38.4 min; p=0.03) and a longer operating room time (165.1 vs 125.8 min; p=0.005).

ABG data

At the time of ValveDepl, the pH ranged from 7.15 to 7.52 and the PaCO2 ranged from 30 to 100 mm Hg. 63% (126/201) of patients had a PaCO2-ValveDepl>50 mm Hg and 26% (52/201) had a PaCO2-ValveDepl>60 mm Hg. A pH<7.20 was recorded in 0.4% (n=7) of patients (table 2).

Table 2 Summary of arterial blood gas data at baseline, at the time of valve deployment or in the postanaesthesia care unit (PACU)

	PaCO2-baseline	PaCO2-ValveDepl	PaCO2-PACU	
Mean±SD	42.5±6.5	54.6±10.6*	43.8±6.7†‡	
Range	27–68	30–100	30–68	
	pH-baseline	pH-ValveDepl	pH-PACU	
Mean±SD	7.41±0.05	7.31±0.06*	7.37±0.04*‡	
Range	7.27–7.52	7.15–7.52	7.23–7.52	
	PaO2-baseline	PaO2-ValveDepl	PaO2-PACU	
Mean±SD	204.0±101.95	260.5±111.6*	145.8±73.1*‡	
Range	(42–469)	(69–605)	(39–358)	
* pP<0.0001 compared tocompared with baseline; @ p compared to baseline;p compared to ValveDepl.

† P<0.01 compared with baseline.

‡ P<0.0001 compared with ValveDepl.

PaCO2arterial partial pressure of carbon dioxidePaO2arterial partial pressure of oxygenValveDeplvalve deployment

Seven patients did not have a baseline ABG available and were therefore excluded from analyses involving PaCO2-%increase. PaCO2-ValveDepl was higher than PaCO2-baseline in 91% of patients. From baseline to the time of ValveDepl, the PaCO2 increased by 28.4% and was associated with a fall in pH. Although the PaCO2 decreased from ValveDepl by 19.8% on arrival to the PACU (p<0.0001), it remained greater than baseline (p=0.01). 15% (n=29) of patients recorded an increase of PaCO2 of more than 50% at the time of ValveDepl compared with baseline.

PaO2 increased from baseline to the time of ValveDepl and decreased in PACU. PaO2 levels were not related to changes in PaCO2.

Demographic data and ABG data

Table 3 summarises the ABG and BIS data at the time of sedation for PaCO2-ValveDepl≤60 mm Hg vs >60 mm Hg, pH-ValveDepl<7.2 vs >7.2 and PaCO2-%increase≤50% vs >50%. pH-ValveDepl and PaCO2-ValveDepl were significantly different for each comparison (p<0.001).

Table 3 Intraoperative arterial blood gas data

	PaCO2-ValveDepl≤60 mm Hg (n=149)	PaCO2-ValveDepl>60 mm Hg (n=52)	P value	PaCO2-%increase<50%(n=165)	PaCO2-%increase>50%(n=29)	P value	pH-ValveDepl>7.2 (n=194)	pH-ValveDepl≤ 7.2 (n=7)	P value	
pH-ValveDeplMean±SD (Range)	7.33±0.05(7.20–7.52)	7.25±0.04(7.15–7.33)	<0.001	7.32±0.06(7.15–7.52)	7.25±0.05(7.17–7.33)	<0.001	7.31±0.06(7.21–7.52)	7.18±0.02(7.15–7.20)	<0.001	
PaCO2-ValveDepl(mm Hg)Mean±SD (Range)	49.8±6.4(30.0–60.0)	68.3±7.8(61.0–100.0)	<0.001	53.0±9.8(30.0–100.0)	63.2±10.0(42.0–89.0)	<0.001	53.8±9.5(30.0–84.0)	77.0±15.0(56.0–100.0)	<0.001	
PaO2-ValveDepl(mm Hg)Mean±SD (Range)	261.3±103.5(80.0–605.0)	258.0±133.5(69.0–579)	0.875	269.5±105.3(80.0–605.0)	225.6±141.1(69.0–579)	0.120	261.9±111.2(69.0–605.0)	213.7±123.2(70.0–401.0)	0.298	
Th compares PaCO2-ValveDepl≤60 mm Hg and >60 mm Hg (201 total patients); PaCO2-%increase from baseline of ≤50% and >50% (194 total patients); and pH-ValveDepl≤7.2 and >7.2 (201 total patients).

PaCO2arterial partial pressure of carbon dioxidePaO2arterial partial pressure of oxygenValveDeplvalve deployment

Table 4 describes the correlation between preoperative demographic variables, organ function data and PaCO2 and pH data. Male sex, younger age and increased weight were significantly associated with PaCO2-ValveDepl>60 mm Hg. Univariate linear regression analyses showed statistically significant linear relationships between higher PaCO2-ValveDepl with younger age (p=0.0025), greater BMI (p=0.0353) and weight (p=0.0052). There was a significant relationship between a larger PaCO2-%increase and male sex (p=0.0003).

Table 4 Preoperative patient demographic and organ function data

	PaCO2-ValveDepl<60 mm Hg (n=149)	PaCO2-ValveDepl>60 mm Hg (n=52)	P value	PaCO2-%increase<50%(n=165)	PaCO2-%increase>50%(n=29)	P value	pH-ValveDepl> 7.2(n=194)	pH-ValveDepl< 7.2 (n=7)	P value	
Sex (%)										
 Female/male	45.6/54.4	25.0/75.0	0.009	43.6/56.4	24.1/75.9	0.064	40.7/59.3	28.6/71.4	0.704	
Age (years)										
 Mean±SD (range)	79.7±8.5(57.0–100.0)	75.9±9.1(49.0–92.0)	0.007	79.2±8.6(49.0–100.0)	76.9±9.0(60-91)	0.183	78.9±8.8(49.0–100.0)	75.0±8.8(66.0–91.0)	0.253	
BMI (kg/m2)										
 Mean±SD (range)	28.6±5.0(18.7–42.6)	30.2±5.9(22.1–48.0)	0.094	29.1±5.2(18.7–42.9)	28.2±6.0(22.0–48.0)	0.205	29.0±5.3(18.7–48.0)	27.7±4.4(23.0–36.3)	0.515	
Weight (kg)										
 Mean±SD (range)	79.7±16.6(43.5–136.1)	87.8±19.9(56.7–147.0)	0.019	81.9±17.9(43.5–147.4)	80.4±17.0(59.0–127.0)	0.520	81.9±17.9(43.5–147.4)	80.3±16.7(64.9–111.6)	0.736	
COPD%	17.5	17.3	1.000	17.6	13.8	0.791	17.0	28.6	0.351	
Asthma%	15.4	9.6	0.359	14.6	3.5	0.135	13.9	14.3	1.000	
Smoking status%										
 Never/previous/current	40.3/55.7/4.0	30.8/63.5/5.8	0.439	39.4/55.8/4.8	31.0/65.5/3.5	0.691	37.6/58.2/4.1	42.9/42.9/14.3	0.284	
OSA%	19.5	28.9	0.175	21.2	24.1	0.807	22.7	0.0	0.351	
Home O2%	2.0	3.9	0.606	3.0	0.0	1.000	2.6	0.0	1.000	
GFR										
 Mean (mL/min) ±SD (range)	54.3±10.1(6.0–60.0)	56.0±10.0(12.0–60.0)	0.039	54.8±9.6(12.0–60.0)	56.9±8.5(26.0–60.0)	0.081	54.7±10.1(6.0–60.0)	56.9±8.3(38.0–60.0)	0.302	
LVEF										
 Mean (%)±SD (range)	59.7±13.2(10.0–80.0)	55.1±14.8(15.0–80.0)	0.054	58.7±13.7(12.0–60.0)	57.7±15.0(15.0–75.0)	0.798	58.4±13.9(10.0–80.0)	60.7±8.4(55.0–75.0)	0.875	
RVSP										
 Mean (mm Hg)±SD (range)	37.6±13.4(18.0–90.0)	37.7±11.1(19.0–66.0)	0.720	36.5±12.5(18.0–90.0)	39.9±11.0(24.0–67.0)	0.092	37.5±13.1(18.0–90.0)	41.0±5.4(36.0–51.0)	0.119	
This compares PaCO2-sedation≤60 mm Hg and >60 mm Hg (201 total patients); PaCO2-%increase from baseline of ≤50% and >50% (194 total patients); and pH≤7.2 and >7.2 (201 total patients).

COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnoea; RVSP, right ventricular systolic pressure

The presence of chronic lung diseases, such as COPD or asthma, home O2 dependence, smoking status and OSA, was not associated with increased PaCO2-ValveDepl, greater PaCO2-%increase, pH-ValveDepl or pH-%decrease.

Medications and ABG data

Higher total and average propofol dose and lower BIS-ValveDepl were significantly associated with PaCO2-ValveDepl>60 mm Hg, but not with PaCO2-%increase>50% or pH-ValveDepl<7.2. Higher total (p<0.0001) and average (p<0.0001) propofol dose were also associated with higher PaCO2-ValveDepl, greater PaCO2-%increase and greater pH-%decrease in separate univariate linear regression analyses. Ketamine administration was significantly associated with PaCO2-increase>50%, but was only administered to seven patients (table 5).

Table 5 Intraoperative anaesthetic (including BIS-ValveDepl) and vasoactive medications

	PaCO2-ValveDepl≤60 mm Hg (n=149)	PaCO2-ValveDepl>60 mm Hg (n=52)	P value	PaCO2-%increase<50%(n=165)	PaCO2-%increase>50%(n=29)	P value	pH-ValveDepl>7.2	pH-ValveDepl≤7.2	P value	
Dexmedetomidine	
 Total (µg)±SD (range)	115.4±50.6(16.0–374)	123.7±61.1(0.0–342.0)	0.561	118.0±51.6(16.0–374.0)	115.5±61.9(0.0–342)	0.428	118.2±53.1(0.0–374.0)	98.4±65.7(38.0–241.0)	0.076	
 Avg (µg/kg/hour)±SD (range)	0.28±0.12(0.08–1.30)	0.27±0.07(0.06–0.42)	0.949	0.28±0.12(0.08–1.30)	0.27±0.07(0.06–0.39)	0.964	0.28±0.11(0.06–1.30)	0.24±0.07(0.13–0.33)	0.384	
Propofol	
 Total (µg)±SD (range)	376.2±201.3(0.0–1162.0)	521.6±332.4(164.0–1960.0)	0.004	401.4±228.6(0.0–1600.0)	498.0±352.2(186.0–1860.0)	0.332	405.3±229.9(0.0–1600.0)	649.3±567.8(202.0–1860.0	0.217	
 Avg (µg/kg/min)±SD (range)	38.4±18.7(0.78–94.2)	47.2±21.7(12.1–114.4)	0.005	39.7±18.7(0.8–94.2)	47.8±25.6(12.1–114.4)	0.115	39.8±18.8(0.78–94.2)	63.9±33.4(27.0–114.4)	0.105	
Fentanyl (any) %	27.5	34.6	0.378	29.1	31.0	0.828	28.9	42.9	0.421	
Ketamine (any) %	4.7	0.0	0.194	1.2	13.8	0.005	3.6	0.0	1.000	
BIS-ValveDepl										
 Mean±SD (range)	49.0±13.5(41–54)	43.7±10.7(37–50)	0.036	48.6±13.3(41–54)	44.7±10.9(39–50)	0.304	47.7±13.2(41–53)	47.4±10.0(38–53)	0.909	
Vasopressors	
 Any during case %	88.6	96.2	0.167	90.3	96.5	0.477	90.2	100	1.000	
 Any at ValveDepl %	77.8	86.5	0.227	79.4	93.1	0.118	79.4	100	0.349	
Vasopressor equivalents	
 Total (µg)±SD (range)	246.4±271.9(0.0–1932.0)	300.5±289.6(0.0–1244.0)	0.180	234.5±260.0(0.0–1932.0)	411.7±332.1(0.0–1244.0)	0.002	256.3±279.4(0.0–1932)	373.1±168.5(134.0–695.5)	0.042	
 Avg (µg/kg/min)±SD (range)	0.024±0.026(0.00–0.128)	0.028±0.024(0.00–0.081)	0.247	0.023±0.024(0.0–0.13)	0.038±0.027(0.0–0.09)	0.002	0.025±0.025(0.00–0.13)	0.043±0.021(0.02–0.08)	0.020	
Inotropes (any) (%)	1.3	9.6	0.013	1.2	17.2	<0.001	3.6	0.0	1.000	
This compares PaCO2-sedation≤60 mm Hg and>60 mm Hg (201 total patients); PaCO2-%increase from baseline of ≤50% and >50% (194 total patients); and pH≤7.2 and >7.2 (201 total patients). Medications are recorded as either ‘any’ (% of patients), total dose or average dose per kilogram during the case (µg/kg/hour or µg/kg/min).

BISBispectral Index Monitoring SystemPaCO2arterial partial pressure of carbon dioxideValveDeplvalve deployment

Both PaCO2-%increase>50% and pH≤7.2 were significantly related to higher total and average vasopressor equivalents. Greater pH-%decrease was significantly associated with more frequent administration of a vasopressor at the time of ValveDepl (p=0.0016), as well as higher total (p=0.0388) and average (p=0.0085) vasopressor equivalents. Patients who received a vasopressor during the case had a higher PaCO2-ValveDepl (55.2±10.6 vs 48.2±9.0; p=0.006), higher PaCO2-%increase (30.6% vs 18%; p=0.03), lower pH-ValveDepl (7.30±0.06 vs 7.36±0.07; p=0.002) and greater pH-%decrease (1.4% vs 0.7%; p=0.024) than those who did not.

Administration of inotropes was more likely in patients with PaCO2-ValveDepl>60 mm Hg and PaCO2-%increase>50%. The average PaCO2-%increase for patients receiving an inotrope was 55.8% compared with a 28.5% for those who did not receive an inotrope (p=0.002), while the average pH-%decrease for those receiving an inotrope was 2.1% compared with a 1.3% for those who did not receive an inotrope (p=0.008).

Outcomes

There was one death (0.5%) at 30 days post TAVR. Two patients suffered a stroke (1%). Six patients (3%) were diagnosed with postprocedure delirium. 11 patients (5.5%) required a pacemaker postoperatively. 35 patients (17.4%) were admitted to the ICU with a mean ICU LOS of 2.5±1.6 days. The mean hospital LOS for the total group was 1.8 days (±1.9 days). Patients admitted to the ICU had a longer hospital LOS (4.3 vs 1.3 days; p<0.001).

25 patients (12.4%) were readmitted to the hospital within 30 days.

A higher likelihood of ICU admission was related to lower average propofol doses (33.6 vs 42.1 µg/kg/min; p<0.005), higher BIS (52.2 vs 46.7; p=0.04), older age (82 vs 78 years; p<0.0001) and greater total (528.6 vs 203.8 µg; p<0.001) and average vasopressor equivalents (0.04 vs 0.02 µg/kg/min; p<0.001). ICU admission was more frequent in patients who required a longer procedure (47.6 vs 37.1 min; p=0.013) and operating room time (156.8 vs 120.9 min; p<0.001). Patients who received inotropes required a longer ICU LOS compared with those who did not (3.0±2.8 vs 0.4±0.9 days; p<0.001).

Hospital LOS was longer in patients who were older (p=0.0139), had a lower GFR (p=0.0061), received higher total and average vasopressor equivalents (p<0.001), required an inotrope (p=0.03) and underwent a longer procedure (p<0.0001). Patients who experienced delirium had longer hospital LOS (p<0.0001).

Outcomes shown in table 6 were not related to PaCO2-ValveDepl, PaCO2-%increase or pH-ValveDepl. This did not change when these analyses were performed based on RVSP of <40 (mean 30.3±5.7) mm Hg, 40–60 (mean 46.7±5.1) mm Hg and >60 (mean 71.0±8.5) mm Hg.

Table 6 Postoperative outcomes

	PaCO2-ValveDepl≤60 mm Hg (n=149)	PaCO2-ValveDepl>60 mm Hg (n=52)	P value	PaCO2-%increase<50%(n=165)	PaCO2-%increase>50%(n=29)	P value	pH-ValveDepl> 7.2	pH-ValveDepl≤7.2	P value	
Admitted to ICU %	16.1	21.1	0.403	16.3	27.6	0.188	17.5	14.3	1.000	
ICU LOS										
 Mean (days)±SD (range)	0.4±1.2 (0.0–8.0)	0.49±1.82 (1.0–2.0)	0.441	0.4±1.1	0.7±1.3	0.162	0.45±1.2	0.14±0.4	0.734	
Hospital LOS										
 Mean (days)±SD (range)	1.8±2.0 (1.0–16.0)	1.9±1.8 (1.0–8.0)	0.738	1.9±2.0 (1.0–16.0)	1.8±1.7 (1.0–5.0)	0.732	1.8±2.0	1.3±0.5	0.767	
Pacemaker %	5.4	5.8	1.000	5.5	6.9	0.671	5.7	0.0	1.000	
30 day readmit %	12.1	13.5	0.809	12.7	10.3	1.000	12.9	0.0	0.600	
30 day mortality %	0.0	1.9	0.259	0.6	0.0	1.000	0.5	0.0	1.000	
Stroke %	1.3	0.0	1.000	1.2	0.0	1.000	1.0	0.0	1.000	
Delirium %	2.0	5.8	0.181	3.6	0.0	0.594	3.1	0.0	1.000	
This compares PaCO2-sedation≤60 mm Hg and >60 mm Hg (201 total patients); PaCO2-%increase from baseline of ≤50% and >50% (194 total patients); and pH≤7.2 and >7.2 (201 total patients).

ICUintensive care unitLOSlength of stayPaCO2arterial partial pressure of carbon dioxideValveDeplvalve deployment

Discussion

Acute intraoperative hypercapnia is common in patients undergoing TAVR under MAC with deep sedation using propofol/dexmedetomidine. Compared with baseline, the PaCO2 increased by an average of 28.4% at the time of ValveDepl, at which time 63% of patients recorded a PaCO2>50 mm Hg and 26% (52/201) had a PaCO2>60 mm Hg.

Patients with AS and heart failure undergoing TAVR are at an increased risk of baseline respiratory dysfunction and hypercapnia.3436 This risk may worsen during the perioperative period. In the present study, intraoperative hypercapnia was associated with higher propofol dose and lower BIS, as well as male sex and increased patient weight. Younger age, which was associated with greater propofol use, was also associated with hypercapnia, but the presence of COPD, asthma, home oxygen dependence, smoking history and OSA was not.

Despite the high incidence of hypercapnia, adverse outcomes in the present study compared favourably with the literature with lower rates of delirium, stroke and 30-day mortality, but there was an increased use of vasoactive medications.68 1216 18 49 Increased need for haemodynamic support was more likely with increased PaCO2-ValveDepl, increased PaCO2-%increase and decreased pH-ValveDepl and was associated with prolonged ICU and hospital LOS. However, PaCO2-ValveDepl, PaCO2-%increase, and pH-ValveDepl were not directly related to ICU admission, ICU and hospital LOS, or other adverse outcomes measured in this study. ICU admission and longer ICU and hospital LOS were instead more likely in older patients with reduced GFR who received less anaesthetic and in those who required longer procedure and operating room times.

These findings reflect the transient nature of anaesthetic effects and variation of anaesthetic technique depending on age and patient comorbidities and suggest that outcomes depended more on patient and procedural factors than anaesthetic management. In addition, permissive mild or moderate hypercapnia is associated with less inflammation and pulmonary tissue oedema, as well as increased bronchodilation and improved lung compliance.45 46 50 Hypercapnia below 60 mm Hg is also reported to improve cardiac performance and mixed venous oxygen saturation.51 Therefore, the absence of a relationship between hypercapnia and adverse outcomes might reflect the differential effects of mild or moderate hypercapnia versus severe hypercapnia and acidosis.

Hypotension and the use of vasoactive medications during TAVR are dictated by baseline cardiovascular function, procedural events and anaesthetic effects. In general, haemodynamic perturbations during MAC are reported to be less compared with GA, with more frequent administration of vasopressors and inotropes with GA (84%–97%) versus MAC (48%–68%).121423 49 In the present study, administration rates of vasopressors and inotropes were closer to those reported for GA than MAC. This could be explained by lower BIS values (median of 46), which were consistent with a range recommended for GA or deep sedation5254 and were generally lower than BIS reported by other studies.13 23 49 However, neither decreased BIS nor higher doses of propofol and dexmedetomidine were associated with an increase in vasoactive medication administration. Therefore, even when considering the deeper sedation provided in the present study, there was an independent effect of PaCO2 and pH on administration of vasoactive medications that was not related to anaesthetic medications or BIS.

Few studies have reported an association between hypercapnia and haemodynamic effects during MAC. In a prospective study of 110 patients undergoing cardiac ablation under MAC/sedation, hypercapnic patients did not have a higher incidence of hypotension, though only 5 patients experienced a PaCO2 greater than 70 mm Hg.22 The authors did not analyse the effect of changes in PaCO2 from baseline. In a small, randomised study comparing GA and MAC, MAC was associated with hypercapnia (50–60 mm Hg) but appeared to have no impact on haemodynamics or vasoactive medication use.23 However, the authors did not specifically evaluate the impact of hypercapnia nor analyse the causes of hypotension. The same group later compared 141 patients who received a combination of propofol and opioid to 157 patients who received dexmedetomidine.55 The propofol/opioid group experienced more hypercapnia (42% vs 25%) and were more likely to receive vasoactive medications (68% vs 25%). However, the analysis did not determine whether PaCO2 was related to administration of vasoactive medications.

The effect of hypercapnic acidosis on cardiac function is phasic. While acidosis directly causes myocardial depression and vascular dilation, moderate hypercapnia increases sympathoadrenal activity and catecholamine synthesis, leading to increased heart rate, cardiac contractility and stroke volume and reduced systemic vascular resistance.2930 5668 With more severe hypercapnia (PaCO2>60 mm Hg) and acidosis (pH<7.2), myocardial depression dominates.30 33 62 68 In a dog model, this phasic change was demonstrated with progressively increasing PaCO2, which was initially accompanied by hypertension but progressed to hypotension with more severe hypercapnia and acidosis.66 The sympathetic response to hypercapnia can also be attenuated by the effects of anaesthetic medications, which unmask the myocardial depressant effects of hypercapnic acidosis.62 67

Hypercapnia increases pulmonary vascular resistance and can cause subsequent right ventricular failure, particularly in patients who already have pulmonary hypertension.5657 61 62 65 6972 Hypercapnia also potentiates regional hypoxic pulmonary vasoconstriction caused by atelectasis, which occurs in up to 90% of patients receiving anaesthesia,50 60 73 further increasing right ventricular afterload.

This study is unique as it reports a high incidence of hypercapnia and associated haemodynamic effects during TAVR with MAC. While there was not a significant relationship between anaesthetic medications and vasoactive medications, the potential cardiovascular impact of anaesthetic medications cannot be minimised. Nonetheless, any haemodynamic instability related to hypercapnia is particularly concerning for patients with AS, many of whom present with preprocedure pulmonary hypertension.374374

Postoperative pulmonary complications occur in <5% of TAVR cases, being greater in patients undergoing GA.49 75 76 Intraoperative respiratory events, however, occur in more than 50% of patients undergoing TAVR with MAC.23 55 The anaesthetic medications administered during MAC can cause intraoperative respiratory depression, which presents as atelectasis, hypoxemia, hypercapnia and a more frequent need for airway support.1119 2325 55 77 In a randomised study comparing GA to MAC using propofol and remifentanil, airway and pulmonary complications occurred in 94% of the MAC patients compared with 13% of GA.23 These included bradypnea, hypoxemia and the need for airway manipulation and bag mask ventilation. In a dose-dependent effect, propofol depresses the hypoxemic and hypercapnic ventilatory responses by inhibiting the response of central chemoreceptors to changes in PaCO2.7880 This effect disappears within 30 min after discontinuation of the propofol infusion.7881 An association between hypercapnia and male sex in the present study may be explained by an increased sensitivity to propofol in men; however, men also have a stronger ventilatory response to CO2.82 Dexmedetomidine can cause upper airway obstruction and reduce the ventilatory response to hypoxemia and hypercapnia.83 In the present study, use of higher doses of propofol but not dexmedetomidine was predictive of hypercapnia. Surprisingly, ketamine administration was more common in patients with a PaCO2-%increase>50%. Although ketamine is not considered a respiratory depressant, a rapid injection may cause transient apnoea.84 85 Conversion from MAC to GA occurs in up to 17% of cases.11 Although conversion to GA is more commonly related to procedural complications and haemodynamic instability,11 12 15 18 49 poor gas exchange and need to improve airway patency may also necessitate prompt conversion to GA.23 77

In the present study, a significant reduction in PaO2 compared with baseline was reported in the PACU, while hypercapnia improved after the discontinuation of sedating medications. Perioperative atelectasis results in regional hypoxia and hypoxic pulmonary vasoconstriction, which optimises ventilation–perfusion matching by reducing pulmonary blood flow to poorly oxygenated regions.50 60 73 Hypercapnia related pulmonary vascular constriction enhances hypoxic pulmonary vasoconstriction, further minimising shunt.50 Theoretically, with reduced sedation and improved ventilation, the reduction of hypercapnia and loss of enhanced hypoxic pulmonary vasoconstriction in the presence of persistent atelectasis could contribute to ventilation–perfusion mismatch, shunt and a lower PaO2.50

Limitations

This was a retrospective study that relied on the EMR and was therefore limited by the accuracy and completeness of the data found in the charts. In addition, medication data collected was an aggregate of doses given over the entirety of each case, whereas PaCO2 was measured at discrete times. Finally, anaesthetic technique was not controlled and led to variability in the use of sedative medications and deployment of airway adjuncts that may have affected our results.

Our study was not powered to find an association to find an association between intraoperative hypercapnia and postoperative outcomes. The observed outcome rates in our patient population were very low and a significantly larger number of patients would have been needed. We surmise that while hypercapnia may have exerted an effect on intraoperative haemodynamics, its effect on postoperative outcomes was likely small compared with the effect of patient comorbidities and procedural complications.

Conclusion

Severe hypercapnia occurs frequently and increases the need for vasoactive medications during TAVR with deep sedation using propofol and dexmedetomidine. This haemodynamic effect appears to be independent of anaesthetic depth. Outcomes, however, are not affected by transient hypercapnia as long as cardiopulmonary function is maintained. Adverse outcomes instead were more likely in older patients who received less anaesthetic and consequently experienced less hypercapnia and patients undergoing longer procedures.

MAC has become a popular anaesthetic for percutaneous transfemoral TAVR. Deep sedation may provide optimal operating conditions, but due to its potential cardiopulmonary effects, local anaesthesia with minimal or moderate sedation may be preferred in many patients. While future studies performing a controlled comparison of anaesthetic techniques may help better delineate the optimal anaesthetic for this patient population, anaesthetic technique should be tailored to fit each patient. If deep sedation is required to minimise patient motion, then hypercapnia and the need for haemodynamic and ventilatory support should be anticipated.

Data availability statement

Data are available in a public, open access repository.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Data availability free text: Data are available in the Dryad database at the following link: https://doi.org//10.5061/dryad.31zcrjdvj.

Patient consent for publication: Not applicable.

Provenance and peer review: Not commissioned; externally peer reviewed.

Ethics approval: The study was approved by the Rhode Island Hospital/Lifespan Institutional Review Board (IRB#1535181). The requirement of informed consent was waived by Rhode Island Hospital/Lifespan IRB because it was a retrospective chart review. All methods were performed in accordance with the relevant guidelines and regulations.
==== Refs
References

1 Otto CM Nishimura RA Bonow RO et al 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation 2021 143 e35 71 10.1161/CIR.0000000000000932 33332149
2 Baumgartner H Falk V Bax JJ et al 2017 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J 2017 38 2739 91 10.1093/eurheartj/ehx391 28886619
3 Neuburger PJ Patel PA Anesthetic Techniques in Transcatheter Aortic Valve Replacement and the Evolving Role of the Anesthesiologist J Cardiothorac Vasc Anesth 2017 31 2175 82 10.1053/j.jvca.2017.03.033 28676187
4 Patel PA Ackermann AM Augoustides JGT et al Anesthetic Evolution in Transcatheter Aortic Valve Replacement: Expert Perspectives From High-Volume Academic Centers in Europe and the United States J Cardiothorac Vasc Anesth 2017 31 777 90 10.1053/j.jvca.2017.02.051 28476446
5 Beurtheret S Karam N Resseguier N et al Femoral Versus Nonfemoral Peripheral Access for Transcatheter Aortic Valve Replacement J Am Coll Cardiol 2019 74 2728 39 10.1016/j.jacc.2019.09.054 31779788
6 Butala NM Chung M Secemsky EA et al Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes JACC Cardiovasc Interv 2020 13 1277 87 10.1016/j.jcin.2020.03.008 32499018
7 Marino M Lilie CJ Culp WC et al The Evolution of Echocardiographic Type and Anesthetic Technique for Transcatheter Aortic Valve Replacement at a High-Volume Transcatheter Aortic Valve Replacement Center J Cardiothorac Vasc Anesth 2019 33 29 35 10.1053/j.jvca.2018.06.022 30087025
8 Sato K Jones PM Sedation versus general anesthesia for transcatheter aortic valve replacement J Thorac Dis 2018 10 S3588 94 10.21037/jtd.2018.08.89 30505539
9 Abbett SK Urman RD Resor CD et al The Effect of Anesthesia Type on Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement J Cardiothorac Vasc Anesth 2021 35 429 35 10.1053/j.jvca.2020.09.083 33023815
10 Hyman MC Vemulapalli S Szeto WY et al Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights from the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry Circulation 2017 136 2132 40 10.1161/CIRCULATIONAHA.116.026656 28864443
11 Mayr NP Michel J Bleiziffer S et al Sedation or general anesthesia for transcatheter aortic valve implantation (TAVI) J Thorac Dis 2015 7 1518 26 10.3978/j.issn.2072-1439.2015.08.21 26543597
12 Stragier H Dubois C Verbrugghe P et al General Anesthesia Versus Monitored Anesthesia Care for Transfemoral Transcatheter Aortic Valve Implantation: A Retrospective Study in a Single Belgian Referral Center J Cardiothorac Vasc Anesth 2019 33 3283 91 10.1053/j.jvca.2019.06.027 31350148
13 Thiele H Kurz T Feistritzer H-J et al General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial Circulation 2020 142 1437 47 10.1161/CIRCULATIONAHA.120.046451 32819145
14 Pani S Cagino J Feustel P et al Patient Selection and Outcomes of Transfemoral Transcatheter Aortic Valve Replacement Performed with Monitored Anesthesia Care Versus General Anesthesia J Cardiothorac Vasc Anesth 2017 31 2049 54 10.1053/j.jvca.2017.04.005 28911896
15 Kiramijyan S Ben-Dor I Koifman E et al Comparison of clinical outcomes with the utilization of monitored anesthesia care vs. general anesthesia in patients undergoing transcatheter aortic valve replacement Cardiovasc Revasc Med 2016 17 384 90 10.1016/j.carrev.2016.02.003 27133500
16 Ahmed A Mathew DM Mathew SM et al General Anesthesia Versus Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement: An Updated Meta-Analysis and Systematic Review J Cardiothorac Vasc Anesth 2023 37 1358 67 10.1053/j.jvca.2023.03.007 37120319
17 Brecker SJD Bleiziffer S Bosmans J et al Impact of Anesthesia Type on Outcomes of Transcatheter Aortic Valve Implantation (from the Multicenter ADVANCE Study) Am J Cardiol 2016 117 1332 8 10.1016/j.amjcard.2016.01.027 26892451
18 Chen EY Sukumar N Dai F et al A Pilot Analysis of the Association Between Types of Monitored Anesthesia Care Drugs and Outcomes in Transfemoral Aortic Valve Replacement Performed Without General Anesthesia J Cardiothorac Vasc Anesth 2018 32 666 71 10.1053/j.jvca.2017.07.009 29277298
19 Armstrong RA Mouton R Definitions of anaesthetic technique and the implications for clinical research Anaesthesia 2018 73 935 40 10.1111/anae.14200 29280142
20 Baulig W Keselj M Baulig B et al Transcutaneous continuous carbon dioxide tension monitoring reduced incidence, degree and duration of hypercapnia during combined regional anaesthesia and monitored anaesthesia care in shoulder surgery patients J Clin Monit Comput 2015 29 499 507 10.1007/s10877-014-9627-x 25312782
21 De Oliveira GS Ahmad S Fitzgerald PC et al Detection of hypoventilation during deep sedation in patients undergoing ambulatory gynaecological hysteroscopy: a comparison between transcutaneous and nasal end-tidal carbon dioxide measurements Br J Anaesth 2010 104 774 8 10.1093/bja/aeq092 20418266
22 Weinmann K Lenz A Heudorfer R et al Continuous transcutaneous carbon-dioxide monitoring to avoid hypercapnia in complex catheter ablations under conscious sedation Int J Cardiol 2021 325 69 75 10.1016/j.ijcard.2020.09.075 33027681
23 Mayr NP Hapfelmeier A Martin K et al Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcome† Br J Anaesth 2016 116 90 9 10.1093/bja/aev294 26424178
24 Bigatello L Pesenti A Respiratory Physiology for the Anesthesiologist Anesthesiology 2019 130 1064 77 10.1097/ALN.0000000000002666 30998510
25 Lagier D Zeng C Fernandez-Bustamante A et al Perioperative Pulmonary Atelectasis: Part II. Clinical Implications Anesthesiology 2022 136 206 36 10.1097/ALN.0000000000004009 34710217
26 Wang L Yang L Yang J et al Effects of Permissive Hypercapnia on Laparoscopic Surgery for Rectal Carcinoma Gastroenterol Res Pract 2019 2019 3903451 10.1155/2019/3903451 31687013
27 Lee JH Kim Y Mun J et al Effects of hypercarbia on arterial oxygenation during one-lung ventilation: prospective randomized crossover study Korean J Anesthesiol 2020 73 534 41 10.4097/kja.19445 32460465
28 Godden DJ Willey RF Fergusson RJ et al Rigid bronchoscopy under intravenous general anaesthesia with oxygen Venturi ventilation Thorax 1982 37 532 4 10.1136/thx.37.7.532 6813987
29 Contou D Fragnoli C Córdoba-Izquierdo A et al Severe but not mild hypercapnia affects the outcome in patients with severe cardiogenic pulmonary edema treated by non-invasive ventilation Ann Intensive Care 2015 5 14 10.1186/s13613-015-0055-y 26059206
30 Bautista AF Akca O Hypercapnia: is it protective in lung injury? Med Gas Res 2013 3 23 10.1186/2045-9912-3-23 24209944
31 Michelet P Carreira S Demoule A et al Effects of acute respiratory and metabolic acidosis on diaphragm muscle obtained from rats Anesthesiology 2015 122 876 83 10.1097/ALN.0000000000000574 25545653
32 van der Schrier R van Velzen M Roozekrans M et al Carbon dioxide tolerability and toxicity in rat and man: A translational study Front Toxicol 2022 4 1001709 10.3389/ftox.2022.1001709 36310693
33 Sieker HO Hickam JB Carbon dioxide intoxication: the clinical syndrome, its etiology and management with particular reference to the use of mechanical respirators Arch Intern Med 1971 127 637 10.1001/archinte.1971.00310160115010
34 Ueno Y Imamura T Oshima A et al Clinical Implications of Changes in Respiratory Instability Following Transcatheter Aortic Valve Replacement J Clin Med 2022 11 280 10.3390/jcm11010280 35012019
35 Konishi M Akiyama E Suzuki H et al Hypercapnia in patients with acute heart failure ESC Heart Fail 2015 2 12 9 10.1002/ehf2.12023 28834643
36 Keymel S Hellhammer K Zeus T et al Severe aortic valve stenosis in the elderly: high prevalence of sleep-related breathing disorders Clin Interv Aging 2015 10 1451 6 10.2147/CIA.S87189 26379430
37 Morozowich ST Murray AW Ramakrishna H Pulmonary Hypertension in Patients for Transcatheter and Surgical Aortic Valve Replacement: A Focus on Outcomes and Perioperative Management J Cardiothorac Vasc Anesth 2018 32 2005 18 10.1053/j.jvca.2017.09.035 29126673
38 Maeder MT Weber L Weilenmann D et al Invasive Hemodynamic Staging Classification of Cardiac Damage in Patients With Aortic Stenosis Undergoing Valve Replacement Can J Cardiol 2020 36 1667 74 10.1016/j.cjca.2020.02.004 32416065
39 Lindman BR Zajarias A Maniar HS et al Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement Heart 2015 101 1656 64 10.1136/heartjnl-2015-308001 26264371
40 Iung B Laouénan C Himbert D et al Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score Heart 2014 100 1016 23 10.1136/heartjnl-2013-305314 24740804
41 Miyamoto J Ohno Y Kamioka N et al Impact of Periprocedural Pulmonary Hypertension on Outcomes After Transcatheter Aortic Valve Replacement J Am Coll Cardiol 2022 80 1601 13 10.1016/j.jacc.2022.08.757 36265955
42 Ratwatte S Stewart S Strange G et al Prevalence of pulmonary hypertension in aortic stenosis and its influence on outcomes Heart 2023 109 1319 26 10.1136/heartjnl-2022-322184 37012043
43 Maeder MT Weber L Rickli H Pulmonary hypertension in aortic valve stenosis Trends Cardiovasc Med 2022 32 73 81 10.1016/j.tcm.2020.12.005 33346089
44 Goradia S Sardaneh AA Narayan SW et al Vasopressor dose equivalence: A scoping review and suggested formula J Crit Care 2021 61 233 40 10.1016/j.jcrc.2020.11.002 33220576
45 Davidson AC Banham S Elliott M et al BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults Thorax 2016 71 Suppl 2 ii1 35 10.1136/thoraxjnl-2015-208209 26976648
46 Morales-Quinteros L Camprubí-Rimblas M Bringué J et al The role of hypercapnia in acute respiratory failure Intensive Care Med Exp 2019 7 39 10.1186/s40635-019-0239-0 31346806
47 Tiruvoipati R Pilcher D Botha J et al Association of Hypercapnia and Hypercapnic Acidosis With Clinical Outcomes in Mechanically Ventilated Patients With Cerebral Injury JAMA Neurol 2018 75 818 26 10.1001/jamaneurol.2018.0123 29554187
48 Chen T Asher S Apruzzese P et al Hypercapnia during transcatheter aortic valve replacement under monitored anesthesia care Dryad Dig Rep 2024 Available 10.5061/dryad.31zcrjdvj
49 He W Huang R-R Shi Q-Y et al Bispectral index-guided sedation in transfemoral transcatheter aortic valve implantation: a retrospective control study J Zhejiang Univ Sci B 2017 18 353 9 10.1631/jzus.B1600522 28378573
50 Ketabchi F Egemnazarov B Schermuly RT et al Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction Am J Physiol Lung Cell Mol Physiol 2009 297 L977 83 10.1152/ajplung.00074.2009 19717554
51 Melberg MB Flaa A Andersen GØ et al Cardiovascular changes induced by targeted mild hypercapnia after out of hospital cardiac arrest. A sub-study of the TAME cardiac arrest trial Resuscitation 2023 193 109970 10.1016/j.resuscitation.2023.109970 37716401
52 Allen M Leslie K Hebbard G et al A randomized controlled trial of light versus deep propofol sedation for elective outpatient colonoscopy: recall, procedural conditions, and recovery Can J Anaesth 2015 62 1169 78 10.1007/s12630-015-0463-3 26335904
53 Avidan MS Zhang L Burnside BA et al Anesthesia awareness and the bispectral index N Engl J Med 2008 358 1097 108 10.1056/NEJMoa0707361 18337600
54 Punjasawadwong Y Phongchiewboon A Bunchungmongkol N Bispectral index for improving anaesthetic delivery and postoperative recovery Cochrane Database Syst Rev 2014 2014 CD003843 10.1002/14651858.CD003843.pub3 24937564
55 Mayr NP Wiesner G van der Starre P et al Dexmedetomidine versus propofol-opioid for sedation in transcatheter aortic valve implantation patients: a retrospective analysis of periprocedural gas exchange and hemodynamic support Can J Anaesth 2018 65 647 57 10.1007/s12630-018-1092-4 29464420
56 Rose CE Althaus JA Kaiser DL et al Acute hypoxemia and hypercapnia: increase in plasma catecholamines in conscious dogs Am J Physiol 1983 245 H924 9 10.1152/ajpheart.1983.245.6.H924 6660313
57 Rose CE Van Benthuysen K Jackson JT et al Right ventricular performance during increased afterload impaired by hypercapnic acidosis in conscious dogs Circ Res 1983 52 76 84 10.1161/01.res.52.1.76 6129076
58 Nahas GG Steinsland OS Increased rate of catecholamine synthesis during respiratory acidosis Respir Physiol 1968 5 108 17 10.1016/0034-5687(68)90080-7 5682730
59 Biesold D Kurosawa M Sato A et al Hypoxia and hypercapnia increase the sympathoadrenal medullary functions in anesthetized, artificially ventilated rats Jpn J Physiol 1989 39 511 22 10.2170/jjphysiol.39.511 2513441
60 Kiely DG Cargill RI Lipworth BJ Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans Chest 1996 109 1215 21 10.1378/chest.109.5.1215 8625670
61 Stengl M Ledvinova L Chvojka J et al Effects of clinically relevant acute hypercapnic and metabolic acidosis on the cardiovascular system: an experimental porcine study Crit Care 2013 17 R303 10.1186/cc13173 24377654
62 Crystal GJ Carbon Dioxide and the Heart: Physiology and Clinical Implications Anesth Analg 2015 121 610 23 10.1213/ANE.0000000000000820 26287294
63 Mas A Saura P Joseph D et al Effect of acute moderate changes in PaCO2 on global hemodynamics and gastric perfusion Crit Care Med 2000 28 360 5 10.1097/00003246-200002000-00012 10708167
64 Potkin RT Swenson ER Resuscitation from severe acute hypercapnia. Determinants of tolerance and survival Chest 1992 102 1742 5 10.1378/chest.102.6.1742 1446482
65 Thorens JB Jolliet P Ritz M et al Effects of rapid permissive hypercapnia on hemodynamics, gas exchange, and oxygen transport and consumption during mechanical ventilation for the acute respiratory distress syndrome Intensive Care Med 1996 22 182 91 10.1007/BF01712235 8727430
66 MILLAR RA Plasma adrenaline and noradrenaline during diffusion respiration J Physiol 1960 150 79 90 10.1113/jphysiol.1960.sp006374 14422433
67 Cullen DJ Eger EI Cardiovascular effects of carbon dioxide in man Anesthesiology 1974 41 345 9 10.1097/00000542-197410000-00006 4412334
68 Almanza-Hurtado A Polanco Guerra C Martínez-Ávila MC et al Hypercapnia from Physiology to Practice Int J Clin Pract 2022 2022 2635616 10.1155/2022/2635616 36225533
69 Nin N Muriel A Peñuelas O et al Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome Intensive Care Med 2017 43 200 8 10.1007/s00134-016-4611-1 28108768
70 Gendreau S Geri G Pham T et al The role of acute hypercapnia on mortality and short-term physiology in patients mechanically ventilated for ARDS: a systematic review and meta-analysis Intensive Care Med 2022 48 517 34 10.1007/s00134-022-06640-1 35294565
71 Chuang I-C Dong H-P Yang R-C et al Effect of carbon dioxide on pulmonary vascular tone at various pulmonary arterial pressure levels induced by endothelin-1 Lung 2010 188 199 207 10.1007/s00408-010-9234-7 20217111
72 Balanos GM Talbot NP Dorrington KL et al Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography J Appl Physiol (1985) 2003 94 1543 51 10.1152/japplphysiol.00890.2002 12482766
73 Zeng C Lagier D Lee J-W et al Perioperative Pulmonary Atelectasis: Part I. Biology and Mechanisms Anesthesiology 2022 136 181 205 10.1097/ALN.0000000000003943 34499087
74 Desai A Desai DM Jamil A et al Outcomes of Preprocedural Pulmonary Hypertension on All-Cause and Cardiac Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review Cureus 2023 15 e34300 10.7759/cureus.34300 36860229
75 Ehret C Rossaint R Foldenauer AC et al Is local anaesthesia a favourable approach for transcatheter aortic valve implantation? A systematic review and meta-analysis comparing local and general anaesthesia BMJ Open 2017 7 e016321 10.1136/bmjopen-2017-016321
76 Shimura T Yamamoto M Kagase A et al The incidence, predictive factors and prognosis of acute pulmonary complications after transcatheter aortic valve implantation Interact Cardiovasc Thorac Surg 2017 25 191 7 10.1093/icvts/ivx075 28453816
77 Mayr NP Transfemoral Transcatheter Aortic Valve Replacement: Conscious Sedation for Everyone? JACC Cardiovasc Interv 2020 13 1288 90 10.1016/j.jcin.2020.03.043 32499019
78 Blouin RT Seifert HA Babenco HD et al Propofol depresses the hypoxic ventilatory response during conscious sedation and isohypercapnia Anesthesiology 1993 79 1177 82 10.1097/00000542-199312000-00007 8267192
79 Goodman NW Black AMS Carter JA Some ventilatory effects of propofol as sole anaesthetic agent Br J Anaesth 1987 59 1497 503 10.1093/bja/59.12.1497 3122806
80 Nieuwenhuijs D Sarton E Teppema LJ et al Respiratory sites of action of propofol: absence of depression of peripheral chemoreflex loop by low-dose propofol Anesthesiology 2001 95 889 95 10.1097/00000542-200110000-00017 11605929
81 Lee MH Yang K-H Lee CS et al The effect-site concentration of propofol producing respiratory depression during spinal anesthesia Korean J Anesthesiol 2011 61 122 6 10.4097/kjae.2011.61.2.122 21927681
82 Buchanan FF Myles PS Cicuttini F Patient sex and its influence on general anaesthesia Anaesth Intensive Care 2009 37 207 18 10.1177/0310057X0903700201 19400484
83 Lodenius Å Ebberyd A Hårdemark Cedborg A et al Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers: A Nonblinded, Randomized Crossover Study Anesthesiology 2016 125 700 15 10.1097/ALN.0000000000001236 27483127
84 Suleiman A Santer P Munoz-Acuna R et al Effects of Ketamine Infusion on Breathing and Encephalography in Spontaneously Breathing ICU Patients J Intensive Care Med 2023 38 299 306 10.1177/08850666221119716 35934953
85 Gómez-Revuelta M Fernández-Rodríguez M Boada-Antón L et al Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression Ther Adv Psychopharmacol 2020 10 2045125320981498 10.1177/2045125320981498 33489089
